Diabetic Foot Ulcer Treatment in Cuba for Oklahoma Families

Heberprot-P is Cuba's pioneering treatment for diabetic foot ulcers. Developed by the Center for Genetic Engineering and Biotechnology (CIGB), it contains recombinant human epidermal growth factor (rEGF) — a protein that stimulates cell growth and new blood vessel formation in wounds. It is administered via intralesional injection directly into the ulcer bed, typically 3 times per week, combined with surgical debridement and specialized dressings.

Heberprot-P is not FDA-approved and is not available in the United States. It is registered in approximately 20 countries and has been used in Cuba for over a decade. The treatment is designed for chronic diabetic foot ulcers — particularly Wagner grade 1–3 ulcers that have not responded to standard wound care (debridement, off-loading, moisture dressings) after 4+ weeks.

The treatment program at Cuban diabetic foot centers includes comprehensive vascular assessment (Doppler, angiography if indicated), infection management (wound cultures, targeted antibiotics), surgical debridement, Heberprot-P intralesional injections, off-loading (total contact casting or specialized footwear), specialized dressings, and rehabilitation. The goal is wound healing and amputation prevention — not a cure for diabetes. Treatment suitability is determined after individual medical evaluation.